Sekar Kathiresan

Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors

Retrieved on: 
Tuesday, June 1, 2021
Cardiology, Biotechnology, Other Health, Health, General Health, Other Science, Medical devices, Research, Genetics, Science, Clinical trials, Sekar Kathiresan

Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the companys board of directors.

Key Points: 
  • Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the companys board of directors.
  • His experience will be incredibly valuable to Verve and our evolution toward clinical development, said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • We look forward to leveraging his insights and knowledge of best practices for financial operations at growing biotechnology companies as we continue to advance our pipeline.
  • Mr. MacLean has more than 30 years of experience in financial leadership roles in the life sciences and other industries.

Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Sekar Kathiresan, Coronary artery disease, Medical specialties, Clinical medicine

Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present a company overview during the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:15 a.m.

Key Points: 
  • Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present a company overview during the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:15 a.m.
  • Dr. Kathiresans presentation will include an overview of Verves strategy to create once-and-done gene editing medicines for coronary heart disease and an update on the companys preclinical progress.
  • Gene editing is a promising new treatment approach for coronary heart disease, the leading cause of death worldwide.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.

Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Sekar Kathiresan

Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place November 30-December 3, 2020.

Key Points: 
  • Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place November 30-December 3, 2020.
  • Dr. Kathiresan will present a corporate overview on Verves strategy to develop one-time gene editing medicines that transform the treatment of coronary heart disease.
  • The presentation will be pre-recorded and available to registered attendees to access on demand throughout the conference.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.

Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020

Retrieved on: 
Monday, November 9, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Aging-associated diseases, Heart diseases, Sekar Kathiresan, Coronary artery disease, Medical specialties, Clinical medicine, Myocardial infarction, Coronary, Cardiovascular disease, Medicine

Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting gene editing as a potentially transformative therapeutic approach at the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually November 13-17, 2020.

Key Points: 
  • Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting gene editing as a potentially transformative therapeutic approach at the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually November 13-17, 2020.
  • Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, will present an overview of Verves approach to develop medicines that safely edit the adult human genome and mimic naturally occurring protective gene variants to confer resistance to coronary heart disease.
  • Coronary heart disease occurs when cholesterol-laden plaque builds up in the arteries of the heart, which can restrict blood flow and lead to a heart attack.
  • The company brings together human genetics analysis and gene editing two of the biggest breakthroughs in 21st century biomedicine to develop transformative therapies for coronary heart disease.

Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit

Retrieved on: 
Friday, September 25, 2020
Health, Genetics, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Sekar Kathiresan

Verve Therapeutics , a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.

Key Points: 
  • Verve Therapeutics , a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.
  • Dr. Kathiresan will present a corporate overview on Thursday, October 1, 2020, at 10:30 a.m.
  • In addition, Dr. Kathiresan will participate in a cardiovascular panel discussion on gene therapy on Thursday, October 1, 2020, at 2:00 p.m.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.

Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series

Retrieved on: 
Thursday, August 13, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Lipids, Branches of biology, Sekar Kathiresan, Cardiology, Lipoproteins, Medical specialties, Low-density lipoprotein, Cholesterol

Verve Therapeutics , a next-generation cardiovascular company, today announced that the companys management team will present a corporate overview as part of Oppenheimers Private Life Sciences Company Call Series on Wednesday, August 19, 2020 at 2:15 p.m.

Key Points: 
  • Verve Therapeutics , a next-generation cardiovascular company, today announced that the companys management team will present a corporate overview as part of Oppenheimers Private Life Sciences Company Call Series on Wednesday, August 19, 2020 at 2:15 p.m.
  • Sekar Kathiresan, M.D., co-founder and chief executive officer; Andrew Bellinger, M.D., Ph.D., chief scientific officer; and Kiran Musunuru, M.D., Ph.D., MPH, co-founder and senior scientific advisor, will participate in the event.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.
  • Verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease.

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Retrieved on: 
Thursday, June 11, 2020
Biotechnology, Other Health, Health, Genetics, Cardiology, Lipids, Branches of biology, Medical specialties, Cardiology, Lipoproteins, Low-density lipoprotein, Coronary artery disease, Cholesterol, Sekar Kathiresan

Verve Therapeutics , a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a persons risk of coronary heart disease, today announced it has raised $63 million in a Series A2 financing from both existing and new investors.

Key Points: 
  • Verve Therapeutics , a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a persons risk of coronary heart disease, today announced it has raised $63 million in a Series A2 financing from both existing and new investors.
  • The company will use the financing to advance its lead program through IND-enabling studies and fuel follow-on pipeline programs.
  • Verve is developing one-time, gene-editing therapies to safely edit targeted genes in the liver to permanently lower LDL cholesterol and triglycerides, key risk factors that cause coronary heart disease.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, October 3, 2019
Biotechnology, Health, Genetics, Cardiology, Sekar Kathiresan, Allergan

Dr. Bellinger joins Verve from Lyndra Therapeutics, a clinical-stage biotechnology company developing ultra-long-acting oral dosage forms to replace daily pills, where he was co-founder and chief scientific officer.

Key Points: 
  • Dr. Bellinger joins Verve from Lyndra Therapeutics, a clinical-stage biotechnology company developing ultra-long-acting oral dosage forms to replace daily pills, where he was co-founder and chief scientific officer.
  • Andrews multidisciplinary background, his experience translating novel scientific innovations into viable clinical candidates, and his deep passion for improving cardiovascular care will be incredibly valuable assets for Verve, said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • Dr. Bellinger is a general cardiologist at Brigham and Womens Hospital and is board-certified in cardiovascular medicine and internal medicine.
  • Prior to joining Verve, he co-founded and served as chief scientific officer of Lyndra Therapeutics, where he helped to build the companys research team and was involved in the companys key partnerships with Gilead and Allergan.

Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit

Retrieved on: 
Wednesday, October 2, 2019
Health, Genetics, Cardiology, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Bioethics, Gene therapy, Molecular biology, Sekar Kathiresan, Coronary artery disease, Gene editing

Verve Therapeutics , a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a persons risk of coronary artery disease, today announced that Sekar Kathiresan, M.D., chief executive officer, will be speaking at the 2019 Jefferies Gene Therapy/Editing Summit.

Key Points: 
  • Verve Therapeutics , a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a persons risk of coronary artery disease, today announced that Sekar Kathiresan, M.D., chief executive officer, will be speaking at the 2019 Jefferies Gene Therapy/Editing Summit.
  • Dr. Kathiresan will give a corporate overview presentation on Tuesday, October 8, 2019, at 12:00 p.m.
  • He will also participate in a panel discussion on gene editing safety and clinical/regulatory insights, to be held on Tuesday, October 8, 2019, at 1:45 p.m.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.